OakChart

uniQure NV

QUREHealthcare·Biotechnology·Netherlands·Small·NASD·Nov 11 • 3:59 PM ET

24.58+1.88 (8.26%)
2026-11-12 06:34 CET
Market cap
1,724.36 USD m
Revenue, TTM
20.17 USD m
Net income, TTM
-232.90 USD m
Free cash flow, TTM
-192.86 USD m
EPS diluted, TTM
-3.55
P/E
-
Compare

Price

QURE against its 20, 50 and 200-day averages
2050200miss
20.0030.0040.0050.0014.9M29.8MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26QUREclose 24.5920-day 23.0650-day 30.35200-day 29.6324.5952w high

52.5% under the 52-week high of 51.72 on 25 Aug 2026. 52-week low 8.73 on 3 Mar 2026. Last 15 sessions, 29.2% high to low

Volume 1.15× normal · the line is the 50-bar volume average

Profile

QURE
52-week range, 37% of the way up
8.7351.72

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

Employees221
IPOFeb 05, 2014
Beta1.15
ATR, 14d1.88
Rel volume1.15
Short float13.05%
Insider own7.08%
Inst own89.92%

Snapshot

6 groups

Valuation

Index-
Market Cap1.72B
Enterprise Value1.62B
Income-232.90M
Sales20.17M
Book/sh4.21
Cash/sh9.53
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees221
IPOFeb 05, 2014

Ratios

P/E-
Forward P/E-
PEG-
P/S85.49
P/B5.84
P/C2.58
P/FCF-
EV/EBITDA-
EV/Sales80.33
Quick Ratio11.52
Current Ratio11.52
Debt/Eq1.92
LT Debt/Eq1.89
Option/ShortYes / Yes

Earnings

EPS (ttm)-3.55
EPS next Y-2.92
EPS next Q-0.86
EPS this Y-9.60%
EPS next Y23.05%
EPS next 5Y29.42%
EPS past 3/5Y-8.45% -4.24%
Sales past 3/5Y-46.73% -15.57%
EPS Y/Y TTM19.12%
Sales Y/Y TTM28.04%
EPS Q/Q36.36%
Sales Q/Q40.39%
EarningsNov 04 BMO
EPS/Sales Surpr.3.87% -15.85%

Ownership

Insider Own7.08%
Insider Trans-8.18%
Inst Own89.92%
Inst Trans1.12%
ROA-25.47%
ROE-88.99%
ROIC-27.36%
Gross Margin13.11%
Oper. Margin-1026.94%
Profit Margin-1154.84%
SMA206.63%
SMA50-19.01%
SMA200-17.04%
Trades-

Technical

Shs Outstand70.04M
Shs Float65.18M
Short Float13.05%
Short Ratio3.95
Short Interest8.51M
52W High51.72 -52.47%
52W Low8.73 181.62%
Volatility7.65% 7.38%
ATR (14)1.88
RSI (14)48.57
Beta1.15
Rel Volume1.15
Avg Volume2.16M
Volume2,469,655

Performance

Perf Week6.75%
Perf Month15.53%
Perf Quarter-47.76%
Perf Half Y-15.72%
Perf YTD2.74%
Perf Year-20.28%
Perf 3Y305.69%
Perf 5Y-25.05%
Perf 10Y202.03%
Recom1.29
Target Price59.33
Prev Close22.71
Price24.58
Change %8.26%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 05, 2026DowngradeBBarclaysOverweight → Equal Weight$28+13.9%
Sep 02, 2026ResumedWWilliam BlairOutperform
Jul 30, 2026UpgradeWWolfe ResearchPeer Perform → Outperform$65+164.4%
Jun 18, 2026UpgradeBBarclaysEqual Weight → Overweight$65+164.4%
Jun 17, 2026UpgradeCCantor FitzgeraldNeutral → Overweight$61+148.1%
Mar 11, 2026UpgradeMMizuhoNeutral → Outperform$35+42.4%
Mar 09, 2026UpgradeWWells FargoEqual Weight → Overweight$60+144.1%
Mar 09, 2026UpgradeRRBC Capital MktsSector Perform → Outperform$35+42.4%
Mar 03, 2026DowngradeWWells FargoOverweight → Equal Weight$15-39.0%
Mar 03, 2026DowngradeMMizuhoOutperform → Neutral$12-51.2%

Peers

Mkt cap
TickerCompanyMkt cap
RGNXRegenxbio Inc560.06M
SRPTSarepta Therapeutics Inc1.79B
PTCTPTC Therapeutics Inc5.42B
MGTXMeiraGTx Holdings plc929.69M
TSHATaysha Gene Therapies Inc1.39B
RAREUltragenyx Pharmaceutical Inc1.70B
BMRNBiomarin Pharmaceutical Inc11.30B
SLDBSolid Biosciences Inc848.24M
VYGRVoyager Therapeutics Inc109.53M
CRSPCRISPR Therapeutics AG4.44B

Insider trading

latest 14 of 84
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Meek David D.DirectorNov 06 '26Sale21.259,080192,95030,667Nov 10 04:04 PM
Meek David D.DirectorNov 06 '26Proposed Sale21.259,080192,950Nov 06 04:00 PM
Kapusta Matthew CCEO, Managing DirectorJul 02 '26Option Exercise19.3921,082408,780540,309Jul 07 04:47 PM
Kapusta Matthew CCEO, Managing DirectorJul 02 '26Sale45.1621,082952,051519,227Jul 07 04:47 PM
Abi-Saab WalidChief Medical OfficerJun 30 '26Option Exercise5.5910,00055,900178,235Jul 02 04:59 PM
Abi-Saab WalidChief Medical OfficerJun 30 '26Sale46.4230,0001,392,600148,235Jul 02 04:59 PM
Kaye JackDirectorJun 30 '26Option Exercise23.4421,167496,23043,056Jul 02 04:54 PM
Kaye JackDirectorJun 30 '26Sale46.4421,167983,03025,996Jul 02 04:54 PM
Kapusta Matthew COfficerJul 02 '26Proposed Sale45.1521,082951,932Jul 02 04:00 PM
Abi-Saab WalidChief Medical OfficerJun 26 '26Sale46.861,43467,197168,235Jun 30 05:06 PM
Abi-Saab WalidChief Medical OfficerJun 30 '26Proposed Sale46.4230,0001,392,643Jun 30 04:01 PM
Kaye JackDirectorJun 30 '26Proposed Sale46.4421,167983,033Jun 30 04:00 PM
Kapusta Matthew CCEO, Managing DirectorJun 25 '26Option Exercise31.7128,716910,584547,943Jun 26 05:15 PM
Kapusta Matthew CCEO, Managing DirectorJun 24 '26Option Exercise31.714,128130,899525,923Jun 26 05:15 PM

Held by

AUM
TickerCompanyAUM
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IBBiShares Biotechnology ETFAUM: 11.36B
JGROJPMorgan Active Growth ETFAUM: 9.31B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
VHTVanguard Health Care ETFAUM: 21.51B
PTHInvesco Dorsey Wright Healthcare Momentum ETFAUM: 291.00M
ITOTiShares Core S&P Total U.S. Stock Market ETFAUM: 95.28B
KOMPState Street SPDR S&P Kensho New Economies Composite ETFAUM: 2.46B
LABUDirexion Daily S&P Biotech Bull 3X ETFAUM: 583.37M

News

latest 14 of 198

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-04-0.880-0.915-0.8795.206.1713
2026Q22026-07-29-1.220-0.822-1.2245.845.4513
2026Q12026-05-05-0.850-0.865-0.8533.565.2012
2025Q42026-03-02-0.570-0.914-0.5955.575.3313
2025Q32025-11-10-1.380-0.903-1.3763.705.7912
2025Q22025-07-29-0.690-0.895-0.6885.265.4012
2025Q12025-05-09-0.820-1.001-0.8221.576.3612
2024Q42025-02-27-1.490-0.653-1.5005.2217.9411
2024Q32024-11-05-0.910-0.993-0.9112.296.8611
2024Q22024-08-01-1.160-1.253-1.15811.136.8411
2024Q12024-05-07-1.360-1.279-1.3568.506.2913
2023Q42024-02-28-1.520-1.455-1.5306.685.6013
2023Q32023-11-07-1.880-0.855-1.8751.4129.4913
2023Q22023-08-01-1.4402.364-1.4372.42166.7115
2023Q12023-05-09-1.630-0.947-1.6285.3328.2515
2022Q42023-02-270.150-0.8860.145102.7322.0117

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-3.110-2.783-3.1057.286.22
2020FY-2.810-3.645-2.81237.51116.44
2021FY7.0406.1697.036524475.82
2022FY-2.710-3.746-2.713106.4830.57
2023FY-6.470-6.312-6.47115.8420.88
2024FY-4.920-4.082-4.92427.1239.44
2025FY-3.460-3.873-3.47316.1015.78
2026FY--3.792--21.21
2027FY--2.918--116.91
2028FY--1.216--366.4
2029FY-1.098--592.88
2030FY-3.613--802.4

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0411166.663.5012.00
2026Q4S2026-10-1311007.623.5016.70
2026Q4S2026-10-1210007.803.5016.70
2026Q4S2026-09-1410417.803.5016.70
2026Q4S2026-09-0811417.733.5016.70
2026Q4S2026-09-0611417.733.5016.70
2026Q4S2026-09-0111517.733.5016.70
2026Q4S2026-07-3010517.883.5016.70
2026Q4S2026-07-2911517.613.5016.70
2026Q4S2026-07-1911106.993.5014.00
2026Q4S2026-07-1511336.993.5014.00
2026Q4S2026-06-2311436.993.5014.00
2026Q4S2026-06-1011346.973.5014.00
2026Q4S2026-05-2812346.813.5014.00

Estimate history

EPS, annual-2.94-2.337-3.105-2.8127.036-2.713-6.471-4.924-3.46-3.5476
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.911-1.5-0.822-0.688-1.376-0.595-0.853-1.224-0.876
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual13.10711.2847.28137.514524.002106.48315.84327.11916.09820.17
Period201720182019202020212022202320242025TTM
Sales, quarterly2.2875.2211.5675.2623.7015.5683.5625.8415.196
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual31.33937.35243.71244.77846.29946.96847.83448.98862.33770.045
Period201720182019202020212022202320242025MRQ
Shares, quarterly48.73948.98854.69854.86662.16662.33763.03369.33570.045
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue20.1716.1027.1215.84106.48524.0037.517.2811.28
Cost of Goods Sold Incl. D&A17.5216.4530.9725.5311.8832.28---
Gross Profit2.64-0.35-3.85-9.6994.60491.73---
Selling, General and Administrative Excl. Other198.55185.12180.43261.66237.03185.86154.33121.6887.81
Research and Development131.87134.43141.63198.97190.51136.87122.4094.1469.01
Other Operating Expense11.200.00-----2.040.14-0.60
Operating Income-207.10-185.47-184.27-271.35-142.43305.87-125.43-121.14-82.83
Interest Expense57.5561.9963.7441.5611.707.473.833.812.16
Unusual Expense2.450.253.6615.604.021.24-0.482.535.19
Net Income Before Taxes-233.81-193.34-237.13-306.56-128.26332.81-141.44-124.20-83.07
Income Taxes-0.915.632.431.92-1.473.22-16.420.000.23
Consolidated Net Income-232.90-198.97-239.56-308.48-126.79329.59-125.02-124.20-83.30
Net Income From Continuing Operations-232.90-198.97-239.56-308.48-126.79329.59-125.02-124.20-83.30
Net Income-232.90-198.97-239.56-308.48-126.79329.59-125.02-124.20-83.30
EPS (Recurring)-3.31-3.46-4.87-6.24-2.657.05-2.82-3.06-2.24
EPS (Basic, Before Extraordinaries)-3.55-3.46-4.92-6.47-2.717.17-2.81-3.11-2.34
EPS (Diluted)-3.55-3.46-4.92-6.47-2.717.04-2.81-3.11-2.34
EBITDA-190.82-170.71-171.63-259.44-133.89313.17-114.78-114.54-75.93
Non-Operating Income (Expense)33.2954.3714.5521.9429.9035.65-12.673.287.11
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense15.0013.1216.5226.3225.3819.2321.8317.538.35
Price To Earnings Ratio-----2.90---
Price To Sales Ratio83.7485.4831.6820.379.951.8542.83393.6891.03
Gross Margin13.11-2.16-14.19-61.1388.8493.84---
Operating Margin-1,026.94-1,152.13-679.50-1,712.71-133.7658.37-334.34-1,663.78-734.07
Net Margin-1,154.84-1,236.00-883.35-1,947.09-119.0762.90-333.27-1,705.82-738.25
Shares Outstanding70.0462.3448.9947.8346.9746.3044.7843.7137.35
Market Capitalization1,724.361,724.36860.80323.681,061.30958.481,607.643,062.91887.66

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue5.205.843.565.573.705.261.575.22
Cost of Goods Sold Incl. D&A5.695.263.183.414.034.294.724.98
Gross Profit-0.490.580.392.16-0.330.98-3.160.25
Selling, General and Administrative Excl. Other53.2945.1747.6352.4748.3543.0041.3145.39
Research and Development34.8232.7130.5133.8332.5433.1334.9238.55
Other Operating Expense-0.077.961.451.852.042.191.966.56
Operating Income-53.71-52.55-48.69-52.16-50.72-44.21-46.42-51.70
Interest Expense14.5814.3714.0314.5716.7215.5915.1114.88
Unusual Expense1.581.26-1.340.951.822.25-4.78-4.17
Net Income Before Taxes-60.54-79.22-53.05-41.00-71.90-37.29-43.14-72.41
Income Taxes0.681.840.49-3.928.630.430.500.86
Consolidated Net Income-61.22-81.06-53.54-37.09-80.53-37.72-43.64-73.26
Net Income From Continuing Operations-61.22-81.06-53.54-37.09-80.53-37.72-43.64-73.26
Net Income-61.22-81.06-53.54-37.09-80.53-37.72-43.64-73.26
EPS (Recurring)-0.86-1.21-0.87-0.58-1.35-0.66-0.88-1.56
EPS (Basic, Before Extraordinaries)-0.88-1.22-0.85-0.59-1.38-0.69-0.82-1.50
EPS (Diluted)-0.88-1.22-0.85-0.59-1.38-0.69-0.82-1.50
EBITDA-48.26-47.64-45.73-49.19-47.09-40.58-41.89-47.35
Non-Operating Income (Expense)9.32-11.058.3426.69-2.6424.7613.61-10.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense4.043.723.783.462.613.773.313.52
Price To Sales Ratio83.74163.4156.7092.66216.8553.2927.8731.81
Gross Margin-9.4310.0010.8638.85-8.8918.55-201.474.71
Operating Margin-1,033.60-899.59-1,366.93-936.80-1,370.49-840.14-2,962.41-990.29
Net Margin-1,178.16-1,387.76-1,502.95-666.06-2,175.87-716.82-2,784.75-1,403.20
Shares Outstanding70.0469.3363.0362.3462.1754.8754.7048.99
Market Capitalization1,724.362,880.101,007.221,474.183,202.58763.19573.22860.80

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments622.54367.52617.89352.84556.26244.93377.79234.90159.37
Short Term Receivables5.865.884.19102.3858.776.620.950.231.59
Inventories0.000.0012.026.920.000.000.000.000.00
Other Current Assets27.5816.8917.7414.6313.227.365.471.451.83
Total Current Assets655.99390.29651.85476.77628.24258.91384.21236.58162.78
Net Property, Plant & Equipment26.3334.0775.3483.2669.0858.4155.5729.1834.28
Total Investments and Advances30.2427.460.0039.980.002.752.932.442.48
Intangible Assets98.1593.4686.8684.3690.323.905.925.7110.10
Deferred Tax Assets8.659.8612.2814.5315.6516.42---
Other Assets5.561.405.366.065.900.000.000.000.00
Total Assets824.91556.54831.69704.96809.18340.40448.63273.91209.64
Short Term Debt Incl. Current Port. of LT Debt3.863.608.348.385.775.525.870.001.05
Accounts Payable5.177.236.5910.982.503.775.683.792.91
Other Current Liabilities53.8929.2358.7556.5528.4918.0420.0816.1815.27
Total Current Liabilities62.9240.0573.6875.9236.7627.3331.6319.9719.23
Long Term Debt532.73497.39524.31134.51129.9566.0267.2035.4719.74
Provision for Risks Charges0.000.000.000.000.000.000.000.00-
Deferred Tax Liabilities7.977.047.548.2612.91----
Other Liabilities22.3918.8018.5010.2733.783.1426.7538.8681.31
Total Liabilities626.01563.29624.02228.96213.4096.49125.5794.30120.29
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity198.90-6.75207.67476.01595.78243.91323.06179.6189.36
Total Shareholders Equity198.90-6.75207.67476.01595.78243.91323.06179.6189.36
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity198.90-6.75207.67476.01595.78243.91323.06179.6189.36
Total Liabilities & Stockholders Equity824.91556.54831.69704.96809.18340.40448.63273.91209.64
Book Value Per Share3.19-0.144.3410.1312.875.457.394.812.85
Tangible Book Value Per Share1.62-2.052.538.3410.925.367.264.662.53
Full-Time Employees221209480501463332248212202
Price to Book Ratio5.8415.421.202.521.616.639.705.9925.61
Return on Assets-28.81-34.51-40.15-16.7557.34-31.69-34.38-34.46-39.64
Return on Equity-207.10-238.46-90.24-23.6678.50-44.10-49.42-61.94-103.61
Return on Invested Capital-27.20-48.83-42.14-20.7745.42-40.34-31.83-38.73-72.65
Quick Ratio10.439.748.686.1917.099.4712.1511.858.47
Current Ratio10.439.748.856.2817.099.4712.1511.858.47

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-229.90-198.97-239.56-308.48-126.79329.59-125.02-124.20-83.30
Depreciation16.0814.7612.6411.908.547.3010.656.676.50
Other Funds (Non Cash)31.4411.4565.3169.5218.05-1.662.4420.956.74
Funds from Operations-179.89-171.17-159.18-225.14-101.68338.44-128.36-96.58-69.84
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-12.24-6.79-23.5579.21-43.38-50.48-6.47-2.11-6.20
Cash from Operating Activities-192.13-177.96-182.73-145.93-145.06287.96-134.83-98.68-76.04
Capital Expenditures-0.74-0.44-11.69-7.15-17.69-17.44-9.48-6.65-4.25
Net Assets From Acquisitions0.000.000.000.00-1.90-49.950.000.000.00
Sale of Fixed Assets and Businesses0.000.00-0.000.000.000.000.000.00
Purchase or Sale of Investments-572.08-321.18174.66-198.53-163.150.000.000.000.00
Purchase of Investments-1,029.16-658.38-359.84-366.44-163.150.000.000.000.00
Sale Or Maturity of Investments457.07337.20534.50167.910.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-572.82-321.62162.97-205.69-182.73-67.39-9.48-6.65-4.25
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock245.73391.902.120.311.4532.367.44248.82143.19
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock245.73391.902.120.311.4532.367.44248.82143.19
Proceedsfrom Stock Options234.87380.740.000.000.0029.570.00242.72286.37
Issuance or Reduction of Debt, Net0.000.00-53.05370.060.0062.490.000.0014.78
Change in Long Term Debt0.000.00-370.060.0064.070.000.0014.78
Issuance of Long Term Debt0.000.00-374.350.0064.070.000.0014.78
Reduction of Long Term Debt0.000.00--4.290.00-0.000.000.00
Net Financing Active Other Cash Flow-0.3523.50-8.56-7.650.000.000.000.000.00
Other Financing Activities Uses0.000.00-8.56-7.650.000.000.000.000.00
Cash from Financing Activities245.38415.40-59.49362.721.4594.867.44248.82157.96
Exchange Rate Effect-1.835.66-4.972.27-1.83-3.763.82-0.11-2.19
Net Change in Cash-521.39-78.53-84.2213.37-328.18311.67-133.05143.3875.49
Free Cash Flow-192.86-178.40-186.10-153.08-162.75270.52-142.10-104.33-78.42
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow-----3.59---
Deferred Taxes & Investment Tax Credit-1.592.431.92-1.473.21-16.420.000.23

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments668.46810.34586.55622.54694.25376.97
Short Term Receivables4.805.783.565.863.885.61
Inventories0.000.000.000.000.000.00
Other Current Assets19.2818.1625.6327.5818.0725.99
Total Current Assets692.55834.27615.74655.99716.19408.57
Net Property, Plant & Equipment20.9022.9824.2826.3328.4831.13
Total Investments and Advances131.5130.2730.1530.2429.9729.74
Intangible Assets86.3686.6994.8098.1599.47100.94
Deferred Tax Assets5.716.368.198.658.779.02
Other Assets3.534.545.545.565.495.49
Total Assets940.55985.10778.71824.91888.38584.89
Short Term Debt Incl. Current Port. of LT Debt7.792.992.993.863.913.91
Accounts Payable6.174.984.405.176.235.54
Income Tax Payable----7.82-
Other Current Liabilities46.1875.3851.8153.8982.6731.48
Total Current Liabilities60.1483.3559.2062.92100.6340.93
Long Term Debt556.65549.18542.66532.73527.75518.05
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities7.707.737.807.977.967.96
Other Liabilities21.4120.8119.7122.3923.3021.95
Total Liabilities645.90661.05629.36626.01659.64588.89
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity294.65324.05149.34198.90228.75-4.00
Total Shareholders Equity294.65324.05149.34198.90228.75-4.00
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity294.65324.05149.34198.90228.75-4.00
Total Liabilities & Stockholders Equity940.55985.10778.71824.91888.38584.89
Book Value Per Share4.214.672.373.193.68-0.07
Tangible Book Value Per Share2.973.420.871.622.08-1.91
Full-Time Employees---221--
Price to Book Ratio5.8419.445.126.50-800.0322.64
Return on Assets-25.47-32.13-30.18-28.81-30.65-30.25
Return on Equity-88.99-157.61-228.24-207.10-165.27-427.47
Return on Invested Capital-7.19-9.28-7.74-5.07-10.65-7.34
Quick Ratio11.5210.0110.4010.437.129.98
Current Ratio11.5210.0110.4010.437.129.98

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-59.88-80.62-53.54-35.86-84.91-40.79
Depreciation5.364.882.962.893.873.94
Other Funds (Non Cash)2.6532.734.76-8.7019.87-0.15
Funds from Operations-51.28-41.15-45.36-42.10-60.06-36.55
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital4.2712.797.12-36.4242.21-6.52
Cash from Operating Activities-47.01-28.36-38.24-78.52-17.85-43.07
Capital Expenditures-0.01-0.47-0.14-0.120.07-0.27
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-267.1753.2498.70-456.8528.5176.87
Purchase of Investments-345.49-231.800.00-451.87-102.38-59.97
Sale Or Maturity of Investments78.32285.0398.70-4.97130.89136.84
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-267.1852.7798.56-456.9628.5876.59
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.09248.310.55-3.22323.633.09
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.09248.310.55-3.22323.633.09
Proceedsfrom Stock Options-1.41241.890.00-5.62314.733.04
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.00-0.3524.580.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.09248.310.55-3.57348.213.09
Exchange Rate Effect0.42-0.77-1.13-0.350.943.58
Net Change in Cash-313.67271.9559.74-539.40359.8840.20
Free Cash Flow-47.01-28.83-38.38-78.64-17.79-43.34

Revenue breakdown

Collaboration revenues2024: 10.87M 2025: 164.00K
Contract manufacturing revenues2024: 6.11M
License revenues2024: 10.13M 2025: 15.93M
Netherlands2024: 27.12M 2025: 16.10M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3013.05%8.5M65.2M1.99M
2026-10-1513.54%8.7M64.5M2.03M
2026-09-3013.52%8.7M64.5M1.90M
2026-09-1515.39%9.9M64.5M1.84M
2026-08-3115.32%9.9M64.5M1.87M
2026-08-1416.71%10.8M64.5M1.92M
2026-07-3117.07%10.7M62.6M2.17M
2026-07-1516.89%10.4M61.4M2.17M
2026-06-3018.73%11.5M61.4M2.17M
2026-06-1520.93%11.8M56.4M1.76M
2026-05-2919.62%11.1M56.6M2.88M
2026-05-1518.39%10.3M56.0M3.28M
2026-04-3018.72%10.8M57.6M3.21M
2026-04-1520.08%11.1M55.3M3.26M
2026-03-3119.80%11.0M55.5M3.34M
2026-03-1322.93%12.7M55.5M3.51M
2026-02-2722.75%12.6M55.5M2.57M
2026-02-1319.34%10.7M55.5M2.28M
2026-01-3020.07%11.4M56.8M3.14M
2026-01-1520.37%11.6M56.8M3.13M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call12.0010.5014.400.005.7150.000.000.944-0.0870.004
call13.009.5013.400.005.3550.000.000.917-0.1250.006
call14.008.5012.400.004.8950.000.000.909-0.1220.006
call15.007.5011.508.604.5831.000.000.899-0.1190.007
call16.006.5010.600.004.2830.000.000.910-0.0860.006
call17.005.509.500.003.7950.000.000.875-0.1120.008
call18.004.807.805.702.74816.0016.000.861-0.1070.008
call19.004.507.104.792.72420.0020.000.843-0.1020.009
call20.002.955.904.262.2379961150.822-0.0960.010
call21.001.854.601.451.69136.000.000.785-0.0980.011
call22.002.304.701.402.1786540.000.749-0.0880.012
call23.001.753.102.161.4991,08083.000.673-0.0980.014
call24.001.352.151.701.1178212350.592-0.0920.015
call25.000.502.051.001.0681,8722570.494-0.0920.015
call26.000.101.950.821.0561,47511.000.402-0.0910.015
call27.000.301.200.601.19968564.000.345-0.0970.014
call28.000.250.800.351.27266396.000.290-0.0950.013
call29.000.200.850.401.43729.000.000.267-0.1030.013
call30.000.000.300.231.12011,0811640.147-0.0560.009
call31.000.000.700.161.24135671.000.136-0.0590.008
call32.000.000.650.101.3557240.000.127-0.0610.008
call33.000.000.850.781.4635420.000.120-0.0640.008
call34.000.000.650.101.56549.000.000.114-0.0660.007
call35.000.000.650.101.66391010.000.109-0.0670.007
call36.000.000.650.301.75537.000.000.104-0.0690.007
call37.000.000.650.051.84469.000.000.101-0.0710.007
call38.000.001.000.261.93018.000.000.097-0.0720.007
call39.000.001.057.282.0122.000.000.094-0.0730.006
call40.000.000.150.011.8796450.000.041-0.0330.003
call41.000.001.200.201.8795.000.000.055-0.0450.004
call42.000.000.851.921.94712.000.000.053-0.0460.004
call43.000.000.900.572.0128.000.000.052-0.0460.004
call44.000.000.905.302.07533.000.000.051-0.0470.004
call45.000.000.850.101.7944150.000.022-0.0200.002
call46.000.000.855.402.19716.000.000.048-0.0480.004
call47.000.000.850.202.25562.000.000.047-0.0480.004
call48.000.000.850.102.31181.000.000.047-0.0490.004
call49.000.000.850.111.99825.000.000.020-0.0210.002
call50.000.000.850.052.4195810.000.045-0.0500.004
call52.500.000.954.902.16195.000.000.019-0.0210.002
call55.000.000.850.052.66794.000.000.042-0.0520.003
call57.500.000.850.102.37171.000.000.017-0.0220.002
call60.000.000.850.032.8881,2670.000.039-0.0530.003
call65.000.000.650.483.0877060.000.037-0.0550.003
call70.000.000.350.063.3481,1810.000.036-0.0550.003
call75.000.000.900.053.4356150.000.034-0.0570.003
put12.000.000.750.203.5031480.00-0.056-0.0850.004
put13.000.001.350.153.27886.000.00-0.066-0.0910.005
put14.000.001.500.152.9656410.00-0.073-0.0890.005
put15.000.000.950.282.6721,0310.00-0.081-0.0870.006
put16.000.000.950.202.39682.000.00-0.090-0.0840.006
put17.000.000.800.402.4772,1850.00-0.125-0.1100.008
put18.000.000.800.482.2019850.00-0.139-0.1050.008
put19.000.000.850.651.9366860.00-0.157-0.1000.009
put20.000.000.700.151.6781,53021.00-0.178-0.0940.010
put21.000.001.000.451.648358337-0.228-0.1070.012
put22.000.000.801.601.2572200.00-0.251-0.0860.012
put23.000.251.051.651.1785120.00-0.327-0.0950.014
put24.000.601.451.201.052556203-0.408-0.0890.015
put25.000.502.001.901.03864830.00-0.506-0.0900.015
put26.001.253.203.301.127484200-0.598-0.0880.015
put27.002.304.803.602.1832020.00-0.655-0.0940.014
put28.002.905.806.402.3904680.00-0.710-0.0920.013
put29.003.506.607.102.44567.000.00-0.733-0.1000.013
put30.004.607.606.802.61948.000.00-0.853-0.0530.009
put31.005.208.709.352.84910.000.00-0.864-0.0550.008
put32.006.409.6010.592.93316.000.00-0.873-0.0580.008
put33.007.1010.4010.502.93329.000.00-0.880-0.0600.008
put34.008.4011.6012.853.21116.000.00-0.886-0.0620.007
put35.009.2012.4013.483.1951,5810.00-0.891-0.0630.007
put36.0010.2013.5014.053.3897.000.00-0.896-0.0650.007
put37.0011.2014.4014.363.43137.000.00-0.899-0.0660.007
put38.0012.2015.5013.753.6168.000.00-0.903-0.0680.007
put39.0013.2016.507.403.7222.000.00-0.906-0.0690.006
put40.0014.3017.4018.013.74967.000.00-0.944-0.0400.004
put41.0014.9018.505.733.9220.000.00-0.945-0.0410.004
put42.0016.1019.5017.454.0170.000.00-0.947-0.0410.004
put43.0017.3020.406.104.03150.000.00-0.948-0.0420.004
put44.0018.0021.506.904.1962.000.00-0.949-0.0420.004
put45.0019.1022.5023.604.28219.000.00-0.950-0.0420.004
put46.0020.1023.500.004.3640.000.00-0.952-0.0430.004
put47.0021.1024.509.104.4444.000.00-0.953-0.0430.004
put48.0022.1025.509.604.52120.000.00-0.953-0.0440.004
put49.0023.1026.509.704.59711.000.00-0.954-0.0440.004
put50.0024.1027.5011.504.6702.000.00-0.955-0.0440.004
put52.5026.5030.0013.004.84420.000.00-0.957-0.0450.004
put55.0029.2032.5014.305.0070.000.00-0.958-0.0450.003
put57.5031.0035.000.005.1600.000.00-0.960-0.0460.003
put60.0033.5037.5018.905.3050.000.00-0.961-0.0470.003
put65.0038.6042.500.005.5720.000.00-0.963-0.0470.003
put70.0043.5047.500.005.8130.000.00-0.964-0.0480.003
put75.0048.6052.500.006.0330.000.00-0.966-0.0490.003

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-104Statement of changes in beneficial ownership of securities2026-11-06SEC
2026-11-06144Filing for proposed sale of securities under Rule 144.SEC
2026-11-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-048-KCurrent report2026-11-04SEC
2026-11-034Statement of changes in beneficial ownership of securities2026-10-30SEC
2026-11-028-KCurrent report2026-10-30SEC
2026-10-16SCHEDULE 13G/ASEC
2026-09-298-KCurrent report2026-09-29SEC
2026-09-028-KCurrent report2026-09-02SEC
2026-08-14SCHEDULE 13GSEC
2026-08-14SCHEDULE 13G/ASEC
2026-07-29S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-07-2910-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-298-KCurrent report2026-07-29SEC
2026-07-20SCHEDULE 13G/ASEC
2026-07-16SCHEDULE 13GSEC
2026-07-074Statement of changes in beneficial ownership of securities2026-07-02SEC
2026-07-02144Filing for proposed sale of securities under Rule 144.SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-06-30144Filing for proposed sale of securities under Rule 144.SEC
2026-06-30144Filing for proposed sale of securities under Rule 144.SEC
2026-06-304Statement of changes in beneficial ownership of securities2026-06-26SEC
2026-06-26144Filing for proposed sale of securities under Rule 144.SEC
2026-06-264Statement of changes in beneficial ownership of securities2026-06-24SEC
2026-06-25144Filing for proposed sale of securities under Rule 144.SEC
2026-06-24144Filing for proposed sale of securities under Rule 144.SEC
2026-06-248-KCurrent report2026-06-23SEC
2026-06-24424B5SEC
2026-06-22424B5SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-1100192.95K1
2026-100000
2026-090000
2026-080000
2026-0700952.05K1
2026-060015.87M21
2026-05001.13M1
2026-040000
2026-0300848.27K8
2026-0200443.68K2
2026-0100804.80K2
2025-120000
2025-11002.03M2

Institutional holders

Manager% owned
Avoro Capital Advisors LLC10.76%
JPMORGAN CHASE & CO7.78%
RTW INVESTMENTS, LP6.30%
STATE STREET CORP4.64%
BlackRock, Inc.3.00%
ORBIMED ADVISORS LLC2.89%
Aberdeen Group plc2.76%
JANE STREET GROUP, LLC2.58%
JENNISON ASSOCIATES LLC2.50%
Boxer Capital Management, LLC2.40%

Funds

Fund% owned
State Street(R) SPDR(R) S&P(R) Biotech ETF3.83%
abrdn Healthcare Investors1.98%
JPMorgan Growth Advantage Fund1.98%
JPMorgan Mid Cap Growth Fund1.53%
abrdn World Healthcare Fund1.27%
VANGUARD EXTENDED MARKET INDEX FUND1.21%
abrdn Life Sciences Investors0.90%
abrdn Healthcare Opportunities Fund0.79%
JPMorgan Small Cap Growth Fund0.78%
iShares Biotechnology ETF0.64%

OakChart. QURE. Cached 15 minutes.